Palvella Therapeutics, Inc.

0 products tracked · names used in filings: Palvella Therapeutics, Inc.

Upcoming milestones

Sun 28 Feb 2027🇺🇸 PDUFA datecompany-announcedin 106 days

QTORIN™ rapamycin: PDUFA target action date (microcystic lymphatic malformations)

Palvella Therapeutics, Inc. (PVLA); rapamycin; NDA; status: set; "patients1 Potentially first FDA approved mLM therapy February 28, 2027 PDUFA Target Action Date 2029+ Additional Potential Approvals in mTOR-Driven Diseases >300,000 U.S."; filed 2026-11-05 · source

Recent milestones

No recent milestones.

Products

No products recorded.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.